Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined Endocrine and Trastuzumab Treatment in Estrogen Receptor-Positive (ER+)/HER2-Overexpressing Xenografts.

被引：0
|
作者：
Malorni, L.
Hilsenbeck, S. G.
Soliz, R. D.
Ward, R. M.
Ryan, A. J.
Osborne, K. C.
Schiff, R.
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] AstraZeneca, Macclesfield, Cheshire, England
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：808S / 808S
页数：1
相关论文
共 50 条
  • [1] Loss of human epidermal growth factor receptor 2 (HER2) expression in HER2-overexpressing esophagogastric (EG) tumors treated with trastuzumab
    Janjigian, Yelena Yuriy
    Riches, Jamie Cathleen
    Ku, Geoffrey Yuyat
    Imtiaz, Tooba
    Capanu, Marinela
    Chou, Joanne F.
    Kelsen, David Paul
    Ilson, David H.
    Berger, Michael F.
    Vakiani, Efsevia
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [2] Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions
    Morabito, Alessandro
    Piccirillo, Maria Carmela
    Falasconi, Fabiano
    De Feo, Gianfranco
    Del Giudice, Antonia
    Bryce, Jane
    Di Maio, Massimo
    De Maio, Ermelinda
    Normanno, Nicola
    Perrone, Francesco
    ONCOLOGIST, 2009, 14 (04): : 378 - 390
  • [3] Circulating tumor DNA (ctDNA) monitoring of estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy
    Pusztai, Lajos
    Kalashnikova, Ekaterina
    Hobbs, Evthokia
    Brown-Glaberman, Ursa
    Mita, Monica
    Klein, Paula
    Yan, Fengting
    Ehsani, Sima
    Razaq, Wajeeha
    Stopeck, Alison
    Bhave, Manali
    Loch, Michelle
    Sardesai, Sagar
    Torres, Evanthia Roussos
    Burkard, Mark
    Okubanjo, Femi
    Gauthier, Eric
    Rodriguez, Angel
    Liu, Minetta
    Kabos, Peter
    CANCER RESEARCH, 2024, 84 (09)
  • [4] Corneal Verticillata After Dual Anti-Epidermal Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Therapy (Vandetanib) for Anaplastic Astrocytoma
    Yeh, Steven
    Fine, Howard A.
    Smith, Janine A.
    CORNEA, 2009, 28 (06) : 699 - 702
  • [5] Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer
    Eroglu, Zeynep
    Tagawa, Tomoko
    Somlo, George
    ONCOLOGIST, 2014, 19 (02): : 135 - 150
  • [6] A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the anti proliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines
    Kim, Elizabeth M. H.
    Lobocki, Catherine
    Dubay, Linda
    Mittal, Vijay K.
    AMERICAN JOURNAL OF SURGERY, 2009, 197 (03): : 331 - 335
  • [7] A specific vascular endothelial growth factor receptor tyrosine kinase inhibitor enhances the anti proliferative effect of trastuzumab in human epidermal growth factor receptor 2 overexpressing breast cancer cell lines Discussion
    Carlin, Arthur M.
    Kim
    Chen, Herbert
    AMERICAN JOURNAL OF SURGERY, 2009, 197 (03): : 335 - 336
  • [8] Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
    Arpino, Grazia
    Gutierrez, Carolina
    Weiss, Heidi
    Rimawi, Mothaffar
    Massarweh, Suleiman
    Bharwani, Lavina
    De Placido, Sabino
    Osborne, C. Kent
    Schiff, Rachel
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (09): : 694 - 705
  • [9] Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
    Alvarez, Ricardo H.
    Hortobagyi, Gabriel N.
    BREAST CANCER, 2013, 20 (02) : 103 - 110
  • [10] Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer
    Ricardo H. Alvarez
    Gabriel N. Hortobagyi
    Breast Cancer, 2013, 20 : 103 - 110
12345